Drug intelligence / Profile preview

iodixanol nasal solution

Development stage: Phase 2
Lead developer: 3E Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

Nasapaque (iodixanol nasal solution) is a nasal spray developed for the treatment of allergic rhinitis. Clinical trials have shown that it reduces allergic rhinoconjunctivitis signs and symptoms. In studies using the Allergen BioCube, Nasapaque demonstrated efficacy for relief of several nasal and ocular allergic rhinitis symptoms, with onset of action as early as 15-20 minutes after treatment and lasting up to 4 hours. The drug was initially developed by OraPharma, Inc. and later continued by 3E Therapeutics Corporation.

Brand names: Nasapaque

Beyond the preview

Go deeper on iodixanol nasal solution.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iodixanol nasal solution.

Explore the full profile